Doctoralia Accelerates by 30% and Is On Track to Reach 18 Million in 2024

The healthtech platform Doctoralia continues its growth in the Spanish market after more than ten years of experience. The company has closed the 2023 financial year with a turnover of twelve million euros and expects to end 2024 with a turnover of between 17 and 18 million, according to Carlos Villaverde, CEO of Doctoralia Spain.

The company’s growth has also been reflected in its number of employees in Spain, where it has 450 workers. “To continue growing, we must continue hiring more staff,” says Villaverde. The executive, who signed on as CEO in May 2023, also stressed that, in recent years, Doctoralia has recorded growth of at least 30% annually .

However, the platform’s expansion strategy in the Spanish market is based on three pillars: organic growth, an attractive value proposition for the patient and the implementation of new technologies through Artificial Intelligence (AI).

The latter will be accompanied by three new launches that the platform is finalizing on a global scale and that could see the light of day before the end of the year. “We are already testing the new AI-based products with some of the professionals who use our platform,” says Villaverde.

Doctoralia will rely on artificial intelligence to continue expanding its business

In line with its ambition to continue growing technologically, Doctoralia has sealed an alliance with Google , integrating itself into the platform so that patients can now book appointments in a single click . In this way, patients searching for a specialist on Google can be redirected to doctors’ online diaries, where they can select the service and date that best suits their needs, and book an appointment.

The platform will also add the services to doctors’ Google business profiles so that patients can choose the service they need directly and access the doctor’s online calendar to select their preferred appointment time. The Book with Google service simplifies the booking process, improves the visibility and accessibility of the medical offer and also contributes to saving time for both doctors and patients.

Currently, the Doctoralia platform in Spain has 150,000 professionals, including doctors, clinics and health centres. The company works with both small and medium-sized clinics and also seeks to improve the patient experience when looking for a doctor.

“We not only want to help patients find professionals in their city, but also to help them use our platform in a comprehensive way, so that they can upload all their medical history in one place, which also benefits doctors,” says Villaverde.

Based in Poland, Doctoralia employs 450 workers in Spain, half of them providing technological support for other countries

The Doctoralia director in Spain had been working for the company as operations director for four years before being appointed country manager . A graduate in Business Administration and Management from Esade, Villaverde also has an MBA from the Indian Institute of Management Bangalore and a master’s degree in Finance from the Management School of the Pompeu Fabra University (UPF). During his almost fifteen years of professional experience, he has worked for companies such as PwC and Eurofins.

Doctoralia began operations in Spain in 2012. The company currently has a team of almost two hundred people in Spain, and also employs more than two hundred workers in its Barcelona offices who provide technological support on a global scale.

The platform operates in thirteen countries and has offices in Amsterdam, Barcelona, ​​Warsaw, Istanbul, Rome, Curitiba, Mexico City, and Bologna. Doctoralia is part of the DocPlanner group, which serves 65 million patients a month and manages nearly eight million appointment bookings per month. The group is backed by venture capital funds and has raised a total of approximately €400 million to date.

__

(Featured image by voltamax via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us